Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,701–4,800 of 10,906
Clinical Development of mRNA Vaccines: Challenges and Opportunities
August, A., Brito, L., Paris, R., & Zaks, T. Z. (2022) · Current topics in microbiology and immunology · doi:10.1007/82_2022_259 · Cited by 14
Self-citationEfficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
Alimehmeti, I. (2021) · Albanian Journal of Trauma and Emergency Surgery · doi:10.32391/ajtes.v5i1.178 · Cited by 13
Virk, A., Johnson, M. G., Roellinger, D. L., Scott, C. G., Sampathkumar, P., Breeher, L. E., & Swift, M. D. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad161 · Cited by 10
Trends in COVID-19 Vaccine Hesitancy and Uptake Among Persons Living With HIV in Washington, DC
Castel, A. D., Barth, S. K., Wilbourn, B. C., Horberg, M. A., Monroe, A. K., & Greenberg, A. E. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003243 · Cited by 12
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
Sa-nguanmoo, N., Namdee, K., Khongkow, M., Ruktanonchai, U., Zhao, Y., & Liang, X. (2021) · Nano Research · doi:10.1007/s12274-021-3832-y · Cited by 13
Li, H. M., Song, P., Li, Y., Tu, S., Mehmood, M., Chen, L., Li, N., & Tian, Q. (2025) · Membranes · doi:10.3390/membranes15050153 · Cited by 18
“These systems integrate ionizable cationic lipids, cholesterol, helper phospholipids, and polyethylene glycolated (PEGylated) lipids through sophisticated intermolecular interactions [10,17].”
Beerlage, A., Leuzinger, K., Valore, L., et al. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13828 · Cited by 12
Maximization of the Minicircle DNA Vaccine Production Expressing SARS-CoV-2 RBD
Ventura, C., Eusébio, D., Gonçalves, A. M., Barroca-Ferreira, J., Costa, D. R. B., Cui, Z., Passarinha, L. A., & Sousa, Â. (2022) · Biomedicines · doi:10.3390/biomedicines10050990 · Cited by 13
Maximizing Completion of the Two-Dose COVID-19 Vaccine Series with Aid from Infographics
Crutcher, M. M., & Seidler, P. M. (2021) · Vaccines · doi:10.3390/vaccines9111229 · Cited by 13
Yuzefpolskiy, Y., Morawski, P. A., Fahning, M. L., Speake, C., Lord, S. M., Chaudhary, A., Morishima, C., Wener, M. H., Kita, M., McCarthy, L. H., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101142 · Cited by 13
Side Effects of COVID-19 Vaccines Among Diabetic Subjects and Healthy Individuals
Khan, F., Khan, M. T., Zaman, S., Mujtaba, S., Batool, A., Ghanghro, Z., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.36005 · Cited by 13
Gonçalves, B. P., Hall, M. D., Jassat, W., Balan, V., Murthy, S., Kartsonaki, C., Semple, M. G., Rojek, A. M., Baruch, J., Reyes, L. F., et al. (2022) · eLife · doi:10.7554/elife.80556 · Cited by 14
Obesity and COVID-19 Pandemics: Epidemiology, Mechanisms, and Management
Yang, Y., Song, Y., & Hou, D. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s441762 · Cited by 16
Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
Monzon‐Posadas, W. O., Zorn, J., Peters, K., Baum, M., Proksch, H., Schlüter, C. B., Menting, T., Pušnik, J., & Streeck, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1066123 · Cited by 13
El-Araby, R. E., Tu, Q., Xie, Y., Aboushousha, T., Li, Z., Xu, X., Zhu, Z. X., Dong, L., & Chen, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0162 · Cited by 15
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
Hara, M., Furue, T., Fukuoka, M., Iwanaga, K., Matsuishi, E., Miike, T., SAKAMOTO, Y., Mukai, N., Kinugasa, Y., Shigyo, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10050779 · Cited by 11
Representation of Race and Sex in Sleep Surgery Studies
Debbaneh, P. M., Ramirez, K. A., Block, N., & Durr, M. L. (2022) · Otolaryngology · doi:10.1177/01945998221088759 · Cited by 13
Investigation of macromolecular transport through tunable collagen hyaluronic acid matrices
Hakim, M. H., Jun, B. H., Ahmadzadegan, A., Babiak, P. M., Xu, Q., Buno, K., Liu, J. C., Ardekani, A. M., Vlachos, P. P., & Solorio, L. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113123 · Cited by 12
Yoshifuji, A., Toda, M., Ryuzaki, M., Kikuchi, K., Kawai, T., Sakai, K., Oyama, E., Koinuma, M., Katayama, K., Uehara, Y., et al. (2022) · Renal Replacement Therapy · doi:10.1186/s41100-022-00427-2 · Cited by 11
Etienne, S., Oliveras, R., Schiboni, G., Durrer, L., Rochat, F., Eib, P., Zahner, M., Osthoff, M. F., Bassetti, S., & Eckstein, J. (2023) · BioMedical Engineering OnLine · doi:10.1186/s12938-023-01081-3 · Cited by 17
Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins
Weng, Y., & Huang, Y. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.02.005 · Cited by 14
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Kampouri, E., Hill, J. A., & Dioverti, M. V. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14144 · Cited by 15
Yoda, T., Suksatit, B., Tokuda, M., & Katsuyama, H. (2022) · Vaccines · doi:10.3390/vaccines10071041 · Cited by 14
Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
Flisiak, R., Pawłowska, M., Rogalska, M., Bociąga‐Jasik, M., Kłos, K., Piekarska, A., & Zarębska‐Michaluk, D. (2021) · Vaccines · doi:10.3390/vaccines9111325 · Cited by 11
Zhu, T., Pawlak, S., Toussi, S. S., Hackman, F., Thompson, K. M., Song, W., Salageanu, J., Winter, E., Shi, H., Winton, J. A., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1174 · Cited by 13
Adamalysins in COVID-19 – Potential mechanisms behind exacerbating the disease
Dias, I. R. D. S. R., Cao, Z., & Kwok, H. F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112970 · Cited by 18
Antibody response to COVID-19 vaccine: A point of view that can help to optimize dose distribution
Pieri, M., Nicolai, E., Ciotti, M., Nuccetelli, M., Sarubbi, S., Pelagalli, M., & Bernardini, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108406 · Cited by 13
Wang, Q., Ning, J., Chen, Y., Li, B., Shi, L., He, T., Zhang, F., Chen, X., Zhai, A., & Wu, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008420 · Cited by 15
COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer
Skarbinski, J., Elkin, E. P., Ziemba, Y. C., Kazemian, E., Wilson, B. M., Siddiqui, H., Schleicher, C. B., Hsiao, C. A., Nugent, J. R., Reckamp, K. L., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2020 · Cited by 13
Reducing COVID-19 Cases and Deaths by Applying Blockchain in Vaccination Rollout Management
Medina, J. H., Cessa-Rojas, R., & Umpaichitra, V. (2021) · IEEE Open Journal of Engineering in Medicine and Biology · doi:10.1109/ojemb.2021.3093774 · Cited by 12
Quantitative and qualitative comparison of mRNA loading techniques into extracellular vesicles
Guarro, M., van Veen, S., Borrós, S., Albertazzi, L., Lecina, M., & Fornaguera, C. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118813 · Cited by 16
Mauro, F. R., Giannarelli, D., Galluzzo, C. M., Visentin, A., Frustaci, A. M., Sportoletti, P., Vitale, C., Reda, G., Gentile, M., Levato, L., et al. (2023) · Cancers · doi:10.3390/cancers15112993 · Cited by 11
The immunopathogenesis of SARS-CoV-2 infection: Overview of lessons learned in the first 5 years
Yang, O. O. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf033 · Cited by 16
Molecular Dynamics Simulation of Lipid Nanoparticles Encapsulating mRNA
Zhang, Z., Cheng, D., Luo, W., Hu, D., Yang, T., Hu, K., Liang, L., Liu, W., & Hu, J. (2024) · Molecules · doi:10.3390/molecules29184409 · Cited by 15
Breakthrough SARS-CoV-2 infections after vaccination: a critical review
Afshar, Z. M., Barary, M., Hosseinzadeh, R., Alijanpour, A., Hosseinzadeh, D., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2051412 · Cited by 14
Advancements in viral vaccine development: from traditional to modern approaches
Kumar, A., Ahmad, F., Sah, B. K., Aljabali, A. A. A., Mishra, Y., & Mishra, V. K. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003203 · Cited by 14
Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Shapiro, J. R., Morgan, R., Leng, S. X., & Klein, S. L. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.836642 · Cited by 13
Assembling the RNA therapeutics toolbox
Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 14
Chang, C., Patel, H., Ferrari, A., Scalzo, T., Petkov, D. I., Xu, H. H., Rossignol, E. D., Palladino, G., & Wen, Y. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126883 · Cited by 16
The clinical potential of l -oligonucleotides: challenges and opportunities
Shearer, V., Yu, C., Han, X., & Sczepanski, J. T. (2024) · Chemical Science · doi:10.1039/d4sc05157b · Cited by 17
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 14
Coria, L. M., Rodriguez, J. M., Demaría, A., Bruno, L. A., Medrano, M. R., Castro, C. P., Castro, E. F., Priore, S. A. D., Hernando-Insúa, A., Kaufmann, I. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45180-8 · Cited by 11
de Bock, E., Herman, E. S., Bastian, O. W., Filipe, M. D., Vriens, M. R., & Richir, M. C. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101859 · Cited by 15
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13
Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery
Żak, M. M., Kaur, K., Yoo, J., Kurian, A. A., Adjmi, M., Mainkar, G., Yoon, S., & Zangi, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092176 · Cited by 13
Li, D., Debbas, P., Cheng, S. C., et al. (2021) · medRxiv · doi:10.1101/2021.12.05.21266089 · Cited by 12
Shiri, T., Evans, M., Talarico, C. A., Morgan, A. R., Mussad, M., Buck, P. O., McEwan, P. C., & Strain, W. D. (2022) · Vaccines · doi:10.3390/vaccines10020140 · Cited by 12
Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults
Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.11.002 · Cited by 15
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Bordat, J., Maury, S., & Leclerc, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100468 · Cited by 15
Tavazzi, E., Pichiecchio, A., Colombo, E., Rigoni, E., Asteggiano, C., Vegezzi, E., Masi, F., Greco, G., Bastianello, S., & Bergamaschi, R. (2023) · Viruses · doi:10.3390/v15071569 · Cited by 13
Zhang, Y., Chen, C., Su, M., Wang, J., Li, C., & Yang, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c04507 · Cited by 12
Xu, J., Zhang, Y., Qu, P., Shamseldin, M. M., Yoo, S. J., Misny, J., Thongpan, I., Mahesh, K. C., Hall, J. M., Evans, J. P., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220403120 · Cited by 15
Abid, A., Khan, M. A., Lee, B. W. H., White, A. J. R., Carnt, N. A., Arshad, S., & Samarawickrama, C. (2022) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2022/9970922 · Cited by 13
Scalabrin, S., Becco, A., Vitale, A., & Nuzzi, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.999251 · Cited by 12
Giant cell myocarditis after first dose of BNT162b2 – a case report
Hirsch, V. G., Schallhorn, S., Zwadlo, C., Diekmann, J., Länger, F. P., Jonigk, D. D., Kempf, T., Schultheiß, H., & Bauersachs, J. K. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2590 · Cited by 13
Tauzin, A., Gong, S., Beaudoin-Bussières, G., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263532 · Cited by 3
Qiao, N., Hori, M., Naito, M., Chang, H., Ogura, S., Suzuki, M., Kimura, T., Fukushima, S., Kim, H. J., Uchida, S., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123515 · Cited by 15
Prabhu, M., Yang, Y. J., Johnston, C. D., Murphy, E. A., Ketas, T. J., Diaz-Tapia, R., Jurkiewicz, M., Racine‐Brzostek, S., Mohammed, I. A., Sukhu, A. C., et al. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100796 · Cited by 16
Editorial: Nanomedicine development and clinical translation
Peng, C. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1458690 · Cited by 15
Lee, H., Punt, J. A., Miller, D. C., Nagpal, A., Smith, C., Sayeed, Y. A., Patel, J., Stojanovic, M. P., Popescu, A., & McCormick, Z. L. (2021) · Pain Medicine · doi:10.1093/pm/pnab063 · Cited by 12
Newman, P. A., Reid, L., Tepjan, S., Fantus, S., Allan, K., Nyoni, T., Guţă, A., & Williams, C. C. (2022) · medRxiv · doi:10.1101/2022.03.15.22272438 · Cited by 12
Sugiyama, A., Kurisu, A., Nagashima, S., Hando, K., Saipova, K., Akhmedova, S., Abe, K., Imada, H., Hussain, M. R. A., Ouoba, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20747-x · Cited by 13
Rajlic, I. L., Guglieri-López, B., Rangoonwala, N., Ivaturi, V. D., Van, L. M., Mori, S., Wipke, B. T., Burdette, D. S., & Attarwala, H. Z. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13142 · Cited by 13
Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12
Nair, S., Nova‐Lamperti, E., Gonzalo Labarca, T., Kulasinghe, A., Short, K. R., Carrión, F., & Salomón, C. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04552-2 · Cited by 14
Neerukonda, S., Vassell, R., Lusvarghi, S., et al. (2021) · bioRxiv · doi:10.1101/2021.11.05.467523 · Cited by 12
Konda, V. C. R., Gokul, T., Poojitha, M. P. M., & Rao, K. U. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2312 · Cited by 12
COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
Shah, M. R., Gabel, A., Beers, S., Salaru, G., Lin, Y., & COOPER, D. L. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.001 · Cited by 13
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination
DeDent, A. M., & Farrand, E. D. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217985 · Cited by 12
Subramanian, V. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad152 · Cited by 11
The impact of COVID-19 on cancer patients
Wekking, D., Senevirathne, T. H., Pearce, J. L., Aiello, M. M., Scartozzi, M., Lambertini, M., Silva, P. D., & Solinas, C. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.004 · Cited by 15
Sengupta, S., Bhattacharyya, D., Kasle, G., Karmakar, S., Sahu, O., Ganguly, A., Addya, S., & Sarma, J. D. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.729622 · Cited by 13
Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges
Hakim, A., Hasan, M. M., Hasan, M., Lokman, S. M., Azim, K. F., Raihan, T., Chowdhury, P. A., & Azad, A. K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.637554 · Cited by 15
Khan, J. A., Satti, L., Bizanjo, M., & Ather, N. A. (2022) · Cureus · doi:10.7759/cureus.23726 · Cited by 12
Clinical Outcomes of Adult Patients Hospitalized with COVID-19 after Vaccination
Kalligeros, M., Shehadeh, F., Mylona, E. K., Kaczynski, M., Kalagara, S., Atalla, E., Tsikala-Vafea, M., & Mylonakis, E. E. (2021) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed6040175 · Cited by 13
Comprehensive Understanding and Field Application of COVID-19 Vaccine
Choi, W. S. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.3.155 · Cited by 11
Liang, Y., & Sun, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2286686 · Cited by 15
Kisakov, D. N., Kisakova, L. A., Borgoyakova, M. B., Starostina, E. V., Taranov, O. S., Ivleva, E. K., Pyankov, O. V., Zaykovskaya, A. V., Щербаков, Д. Н., Рудометов, А. П., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112259 · Cited by 13
Seguridad de las vacunas contra la COVID-19
Chaparro-Mérida, N. A., Samper, D. M., & Lacato, A. O. F. (2021) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2021.384.9308 · Cited by 25
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 12
Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
Rousculp, M. D., Hollis, K. A., ZIEMIECKI, R. M., Odom, D. M., Marchese, A. M., Montazeri, M., Odak, S., Jackson, L., Miller, A., & Toback, S. L. (2024) · Vaccines · doi:10.3390/vaccines12010083 · Cited by 10
Mossadeq, S., Shah, R., Shah, V., & Bagul, M. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02455-x · Cited by 13
Waisner, H., Grieshaber, B., Saud, R., Henke, W., Stephens, E., & Kalamvoki, M. (2022) · bioRxiv · doi:10.1128/spectrum.03707-22 · Cited by 8
Damodharan, K., Arumugam, G. S., Ganesan, S., Doble, M., & Thennarasu, S. (2021) · RSC Advances · doi:10.1039/d0ra09668g · Cited by 14
The path to find an HIV vaccine
Gray, G., & Corey, L. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25749 · Cited by 11
Self-citationMinami, S., Kotaki, T., Sakai, Y., Okamura, S., Torii, S., Ono, C., Motooka, D., Hamajima, R., Nouda, R., Nurdin, J. A., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02859-23 · Cited by 10
Hatfield, K. M., Baggs, J. M., Wolford, H. M., Fang, M., Sattar, A. A., Montgomery, K. S., Jin, S., Jernigan, J. A., & Pilishvili, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac562 · Cited by 12
Yau, K., Tam, P. Y., Chan, C. T., Hu, Q., Qi, F., Abe, K. T., Kurtesi, A., Jiang, Y., Estrada-Codecido, J., Brown, T., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000328 · Cited by 11
Seong, G. M., Baek, A.-R., Baek, M. S., Kim, W., Kim, J. H., Lee, B. Y., Na, Y. S., & Lee, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121258 · Cited by 11
Jaber, A., Patel, M. H., Sylvester, A., Yarussi, M., Kalina, J. T., Mendoza, J. P., Avila, R. L., & Tremblay, M. A. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00448-x · Cited by 13
mRNA vaccines: hope beneath the hype
Extance, A. (2021) · BMJ · doi:10.1136/bmj.n2744 · Cited by 11
Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2
Lee, K.-M., Lin, S., Wu, C.-J., & Kuo, R. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.01.002 · Cited by 15
Effects of various mRNA-LNP vaccine doses on neuroinflammation in BALB/c mice
Kirshina, A., Kazakova, A., Kolosova, E., Имашева, Е. А., Vasileva, O., Zaborova, O. V., Terenin, I. M., Muslimov, A., & Reshetnikov, V. V. (2022) · Вестник Российского государственного медицинского университета · doi:10.24075/brsmu.2022.068 · Cited by 19
RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
Abdelzaher, H. M., Gabr, A. S., Saleh, B. M., Gawad, R. M. A., Nour, A. A., & Abdelnaser, A. (2021) · Vaccines · doi:10.3390/vaccines9111211 · Cited by 13
Activity-based epidemic propagation and contact network scaling in auto-dependent metropolitan areas
Kumar, N., Oke, J. B., & Nahmias–Biran, B.-H. (2021) · Scientific Reports · doi:10.1038/s41598-021-01522-w · Cited by 11
CALMS: Modelling the long-term health and economic impact of Covid-19 using agent-based simulation
Mintram, K. S., Anagnostou, A., Anokye, N., Okine, E., Groen, D., Saha, A., Abubakar, N. T., Islam, T., Daroge, H., Ghorbani, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272664 · Cited by 14
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.